## Jangik I Lee

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5060379/publications.pdf

Version: 2024-02-01

		1163117	996975	
15	254	8	15	
papers	citations	h-index	g-index	
15	15	15	382	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis. Tuberculosis, 2021, 127, 102052.	1.9	2
2	Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e521-e529.	0.4	3
3	Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. Investigational New Drugs, 2020, 38, 812-820.	2.6	33
4	Population pharmacokinetics of vactosertib, a new TGF- $\hat{l}^2$ receptor type $\hat{l}^{TM}$ inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 173-183.	2.3	22
5	Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia. International Journal of Hematology, 2020, 111, 417-426.	1.6	5
6	Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis. International Journal of Pharmaceutics, 2020, 578, 119103.	5.2	6
7	Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1006-1013.	1.5	11
8	Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ Open, 2019, 9, e027940.	1.9	30
9	Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. Cancer Medicine, 2018, 7, 1766-1773.	2.8	4
10	Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Critical Care, 2017, 21, 319.	5.8	69
11	Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. Leukemia and Lymphoma, 2016, 57, 1856-1864.	1.3	8
12	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0153502.	2.5	6
13	Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis, 2015, 95, 54-59.	1.9	27
14	Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKK $\hat{I}^2$ inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2655-2660.	2.2	23
15	Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers. Clinical Therapeutics, 2014, 36, 1064-1071.	2.5	5